IP Library › Granted Patent US 11,306,151
Granted Patent B2
US 11,306,151 · App. 15/733,554 · Granted Apr 19, 2022

Anti-TIP-1 antibodies and uses thereof

Inventors: Minghan Wang (San Diego, CA); Hui Zou (Dallas, TX); Joshua Oaks (San Diego, CA)
Assignee: Phanes Therapeutics, Inc.
C07K16/30G01N33/57492C07K2317/31C07K2317/56C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,306,151
App. No.
15/733,554
Granted
Apr 19, 2022
Kind
B2
Abstract

Anti-TIP-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.

Claims (17)

1. An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1), HCDR2, and HCDR3, and a light chain variable region comprising a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of

SEQ ID NOs:3, 4, 5, 6, 7, and 8, respectively;

wherein the antibody or antigen-binding fragment thereof specifically binds TIP-1.

2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising a heavy chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO:1 and a light chain variable region having a polypeptide sequence at least 95% identical to SEQ ID NO:2.

3. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising:

a. a heavy chain variable region having the polypeptide sequence of SEQ ID NO:1, and a light chain variable region having the polypeptide sequence of SEQ ID NO:2.

4. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein the monoclonal antibody or antigen-binding fragment thereof is capable of inducing effector-mediated tumor cell lysis.

5. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is chimeric or humanized.

6. A pharmaceutical composition, comprising the isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

7. An isolated bispecific antibody or antigen-binding fragment thereof comprising the monoclonal antibody or antigen-binding fragment thereof of claim 1 .

8. A pharmaceutical composition comprising the isolated bispecific antibody or antigen-binding fragment thereof of claim 7 and a pharmaceutically acceptable carrier.

9. A method of determining a level of TIP-1 in a subject, the method comprising:

a. obtaining a sample from the subject;

b. contacting the sample with an isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 ; and

c. determining a level of TIP-1 in the subject.

10. The method of claim 9 , wherein the sample is a tissue sample or a blood sample.

11. The method of claim 10 , wherein the tissue sample is a cancer tissue sample.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2020
From: WANG, MINGHAN; ZOU, HUI; OAKS, JOSHUA
To: PHANES THERAPEUTICS, INC.
Reel/Frame 053602/0911 →
Continuity (2)
Provisional Application 62640123 · Mar 8, 2018
Related Publication 20200399396A1 · Dec 24, 2020
Cited By (1)
US 12,735,481